Jasper Therapeutics, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between Nov. 30, 2023 and July 3, 2025 (the “Class Period”).

Investor suffering losses in excess of $50,000 are advised to contact the firm now for more information on how to participate.

What Is this Case About?

From November 30, 2023 through July 3, 2025, Jasper Therapeutics allegedly issued a series of positive statements about its clinical programs, including the BEACON (CSU) and SpotLight urticaria trials, as well as its asthma and SCID studies. For example, in quarterly updates and press releases, the Company highlighted “positive initial data,” high response rates, and “great progress” across its pipeline, while omitting any mention of significant problems affecting key trials.

What Happened?

On July 7, 2025, Jasper Therapeutics issued a press release disclosing that two cohorts in its Phase 1/2a BEACON (CSU) trial “appeared to be confounded by an issue with one drug product lot,” with 10 of 13 patients dosed from the affected lot failing to improve. On this news, Jasper Therapeutics's stock price fell $3.73 per share, or 55.1%, to close at $3.04 on July 7, 2025.

Soon after, a securities fraud class action complaint was filed alleging defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company’s products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; and (iv) accordingly, the Company’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated.

What Can Investors Do?

Shareholders who purchased shares of Jasper during the Class Period are encouraged to contact the firm regarding possible lead plaintiff appointment. Participating Jasper investors must act no later than November 18, 2025. Appointment as lead plaintiff is not required to partake in any recovery as a class member.

About Shamis Gentile

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.